LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 732 | 3694 | 0.1983 | -0.3356 |
| SK-BR-3 | CHIR-99021 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 2245 | 3694 | 0.6079 | 0.3468 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 881 | 3694 | 0.2386 | -0.2685 |
| SK-BR-3 | R406 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 2765 | 3694 | 0.7485 | 0.5810 |
| SK-BR-3 | Pictilisib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1499 | 3694 | 0.4058 | 0.0100 |
| SK-BR-3 | Gefitinib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1677 | 3694 | 0.4542 | 0.0906 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP6 | 72 | hr | 1476 | 688 | 3694 | 0.1864 | -0.3554 |
| SK-BR-3 | GSK1059615 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 843 | 3694 | 0.2283 | -0.2857 |
| SK-BR-3 | GSK1904529A | 10.0 | uM | LJP6 | 72 | hr | 1476 | 3712 | 3694 | 1.0049 | 1.0081 |
| SK-BR-3 | Omipalisib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 765 | 3694 | 0.2073 | -0.3207 |
| SK-BR-3 | GW843682X | 10.0 | uM | LJP6 | 72 | hr | 1476 | 2206 | 3694 | 0.5974 | 0.3292 |
| SK-BR-3 | HG-5-88-01 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1696 | 3694 | 0.4591 | 0.0989 |
| SK-BR-3 | Imatinib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 3656 | 3694 | 0.9898 | 0.9830 |
| SK-BR-3 | JNK-9L | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1203 | 3694 | 0.3258 | -0.1233 |
| SK-BR-3 | JW-7-24-1 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1074 | 3694 | 0.2907 | -0.1816 |
| SK-BR-3 | Lapatinib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1740 | 3694 | 0.4712 | 0.1190 |
| SK-BR-3 | Linifanib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1846 | 3694 | 0.4999 | 0.1668 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP6 | 72 | hr | 1476 | 544 | 3694 | 0.1474 | -0.4204 |
| SK-BR-3 | MK2206 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1342 | 3694 | 0.3634 | -0.0606 |
| SK-BR-3 | Nintedanib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 977 | 3694 | 0.2646 | -0.2252 |
| SK-BR-3 | NVP-TAE684 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 965 | 3694 | 0.2613 | -0.2306 |
| SK-BR-3 | Palbociclib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 2583 | 3694 | 0.6993 | 0.4991 |
| SK-BR-3 | PD0325901 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1787 | 3694 | 0.4838 | 0.1401 |
| SK-BR-3 | PD173074 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1980 | 3694 | 0.5360 | 0.2270 |
| SK-BR-3 | PF562271 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1246 | 3694 | 0.3375 | -0.1038 |